Cardiol Therapeutics Inc. — Form F-10/A
Filed September 16, 2026 · analyzed by the Registration Agent
F-10/A
— Neutral
significance 28/100
What the filing says
Cardiol Therapeutics Inc. filed Amendment No. 1 to Form F-10 on September 16, 2026, establishing a base shelf prospectus permitting the issuance of up to US$150,000,000 in common shares, debt securities, warrants, subscription receipts, or units over a 25-month period. The filing incorporates financial statements through June 30, 2026, showing the company has advanced its Phase III MAVERIC trial (CardiolRx for recurrent pericarditis) with $9.5M cumulative spend and is pursuing CRD-38 IND-enabling studies ($1.4M spent). As of June 30, 2026, the company held $26.1M cash and had 120.7M shares outstanding at C$2.77/share on TSX.
Why this rating
Shelf prospectus is routine capital-raising mechanism. US$150M capacity exceeds disclosed milestones (~$27M) but is standard for biotech uncertainty. Company is pre-revenue, cash-funded R&D stage; offering provides optionality but no immediate financing announced.
Extracted items
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.